
    
      This is a placebo controlled double blind study of sorafenib versus placebo of in patients
      with high risk biochemical recurrence of prostate cancer. High risk characteristics include a
      short PSADT (<9 months) or high Gleason score (>8), characteristics, which correspond to a
      higher risk of prostate cancer specific mortality in patients with biochemical recurrence
      following radiation therapy or radical prostatectomy.
    
  